Emergent Biosolutions Inc (EBS) Position Reduced by Colony Group LLC

Colony Group LLC cut its stake in shares of Emergent Biosolutions Inc (NYSE:EBS) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,610 shares of the biopharmaceutical company’s stock after selling 895 shares during the period. Colony Group LLC owned about 0.06% of Emergent Biosolutions worth $1,874,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Rehmann Capital Advisory Group boosted its stake in Emergent Biosolutions by 78.7% in the 4th quarter. Rehmann Capital Advisory Group now owns 452 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 199 shares during the period. Quantamental Technologies LLC bought a new stake in Emergent Biosolutions in the 4th quarter worth approximately $29,000. Semmax Financial Advisors Inc. bought a new stake in Emergent Biosolutions in the 4th quarter worth approximately $30,000. Bronfman E.L. Rothschild L.P. lifted its position in Emergent Biosolutions by 1,108.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,112 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 1,020 shares during the last quarter. Finally, Clarus Wealth Advisors lifted its position in Emergent Biosolutions by 1,518.0% in the 4th quarter. Clarus Wealth Advisors now owns 1,618 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,518 shares during the last quarter. Institutional investors and hedge funds own 84.63% of the company’s stock.

EBS has been the topic of several research analyst reports. Wells Fargo & Co set a $68.00 target price on Emergent Biosolutions and gave the company a “hold” rating in a research note on Friday, March 1st. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. ValuEngine raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. TheStreet cut Emergent Biosolutions from a “b+” rating to a “c+” rating in a research note on Tuesday, March 12th. Finally, Cantor Fitzgerald set a $75.00 price target on Emergent Biosolutions and gave the stock a “buy” rating in a research note on Friday, January 25th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Emergent Biosolutions presently has a consensus rating of “Buy” and a consensus price target of $70.43.

In other news, Chairman Fuad El-Hibri sold 10,369 shares of the firm’s stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $59.65, for a total value of $618,510.85. Following the completion of the sale, the chairman now directly owns 1,478,306 shares of the company’s stock, valued at approximately $88,180,952.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Adam Havey sold 3,043 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $58.11, for a total value of $176,828.73. Following the completion of the sale, the executive vice president now directly owns 36,694 shares of the company’s stock, valued at $2,132,288.34. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,132 shares of company stock valued at $3,411,113. Company insiders own 13.40% of the company’s stock.

Emergent Biosolutions stock traded down $0.22 during mid-day trading on Monday, reaching $52.89. 300,127 shares of the stock traded hands, compared to its average volume of 501,850. The stock has a market cap of $2.72 billion, a PE ratio of 22.70, a price-to-earnings-growth ratio of 0.83 and a beta of 1.33. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.07 and a current ratio of 3.10. Emergent Biosolutions Inc has a 12-month low of $46.93 and a 12-month high of $73.89.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.14. The business had revenue of $270.70 million during the quarter, compared to analysts’ expectations of $269.05 million. Emergent Biosolutions had a return on equity of 12.61% and a net margin of 8.02%. The business’s quarterly revenue was up 39.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.74 earnings per share. As a group, sell-side analysts predict that Emergent Biosolutions Inc will post 3.23 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Emergent Biosolutions Inc (EBS) Position Reduced by Colony Group LLC” was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/15/colony-group-llc-sells-895-shares-of-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Further Reading: Stock Split

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.